Clinical Trial Update: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study of a MELK inhibitor for advanced breast cancer including triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MELK inhibitor (MELK inhibitor)

Snippet

Sponsor: OncoTherapy Science, Inc. | Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING